Novo Nordisk A/S (NVO) News

Novo Nordisk A/S (NVO): $100.70

-1.40 (-1.37%)

POWR Rating

Component Grades













Filter NVO News Items

NVO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVO News Highlights

  • For NVO, its 30 day story count is now at 88.
  • Over the past 28 days, the trend for NVO's stories per day has been choppy and unclear. It has oscillated between 1 and 17.
  • MA, GLP and GENE are the most mentioned tickers in articles about NVO.

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Novo Nordisk Prepares Phase 3 Study for Haemophilia Drug, According to Clinical Trials Database

(PLX AI) - Novo Nordisk is preparing to start a phase 3 trial for its Mim8 haemophilia drug, according to data the company posted on The study is investigating how Mim8 works c

FinanzNachrichten | September 22, 2021

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 20 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period

Yahoo | September 20, 2021

Antidiabetic Biguanides Market Future Outlook 2027 with Merck Group, Sanofi, AstraZeneca, Eli Lilly and Company, Novo Nordisk

Antidiabetic Biguanides Market size is anticipated to reach substantial + 9.0% CAGR during the forecast period 2021-2027. A2Z Market Research announces the release of Antidiabetic Biguanides Market research report. The market is predictable to grow at a healthy pace in the

OpenPR | September 16, 2021

What were the ten highest paying salaries in Croatia last year

According to the annual financial reports, the highest average net salary among the 1,000 largest companies in Croatia was paid last year at Microsoft Croatia and amounted to 36,330 Kuna, or around 4,800 Euros, per month. This IT company surpassed the Croatian branches of three pharmaceutical multinationals - Roche, Boehringer Ingelheim and Novo Nordisk. GlaxoSmithKline and Medtronic Adriatic, which are also in the top 10 in terms of paid average salaries, confirm that last, the pandemic year, was the best for the world''s pharmaceutical giants, writes Lider . Among the ten highest average salaries, there is only one Croatian-owned company - Emil Tedeschi''s Atlantic Group. Last year, the thousand largest Croatian companies paid an average net salary of 7,282 Kuna. According to this ind...

The Dubrovnik Times | September 14, 2021

Preventive Healthcare and Wellness Market Future Growth Outlook 2021-2027 | Phoenix Medicine., Aetna, Novo Nordisk

Preventive Healthcare and Wellness Market is growing at a 27.30% CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market. Preventive health care, also known

OpenPR | September 12, 2021

The 10 Richest People on Wall Street and How to Invest in Them

Knowing what stocks the richest people on Wall Street currently own could help you find potential winners for your portfolio.

Thomas Niel on InvestorPlace | September 10, 2021

Bleeding Disorders Market will Witness Huge Growth till 2027 & Covid-19 Analysis | Pfizer, Novo Nordisk

This remarkable Bleeding Disorders market report is the precise depiction of the whole market scenario. Studying potential deficits along with the issues encountered by major industries is possible through this report. It focuses on social, financial and economic elements related

OpenPR | September 9, 2021

2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)

These two companies have outperformed the market in the past year, and they are likely to continue doing so.

Yahoo | September 9, 2021

Here's Why Novo Nordisk (NVO) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Yahoo | September 9, 2021

Haemophilia Treatment Market Competitive Outlook | Key Players CSL Behring, Roche, Novo Nordisk

Haemophilia Treatment Market research report is the new analysis data source added by A2Z Market Research. Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene

OpenPR | September 8, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8482 seconds.